Back to Search
Start Over
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study.
- Source :
-
Clinical rheumatology [Clin Rheumatol] 2018 Aug; Vol. 37 (8), pp. 2233-2240. Date of Electronic Publication: 2018 May 17. - Publication Year :
- 2018
-
Abstract
- A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 patients/year. Safety concerns were more frequent among patients aged ≥ 65 years compared with patients < 16 years (p = 0.002). No differences were detected in the frequency of safety concerns between monotherapy and combination therapy with immunosuppressants (p = 0.055), but a significant difference was observed when injection site reactions were excluded from AE (p = 0.01). No differences were identified in relation to gender (p = 0.462), different lines of biologic therapy (p = 0.775), and different dosages (p = 0.70 ANA; p = 0.39 CAN). The overall drug retention rate was significantly different according to the occurrence of safety concerns (p value < 0.0001); distinguishing between ANA and CAN, significance was maintained only for ANA (p < 0.0001 ANA; p > 0.05 CAN). Treatment duration was the only variable associated with onset of AE (OR = 0.399 [C.I. 0.250-0.638], p = 0.0001). ANA and CAN have shown an excellent safety profile; the risk for AE and sAE tends to decrease over time from the start of IL-1 inhibition.
- Subjects :
- Adolescent
Adult
Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal, Humanized
Child
Female
Humans
Interleukin 1 Receptor Antagonist Protein adverse effects
Logistic Models
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Young Adult
Antibodies, Monoclonal therapeutic use
Autoimmune Diseases drug therapy
Interleukin 1 Receptor Antagonist Protein therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1434-9949
- Volume :
- 37
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Clinical rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 29770930
- Full Text :
- https://doi.org/10.1007/s10067-018-4119-x